Diagnostic performance of 18 fluorodesoxyglucose positron emission/computed tomography and magnetic resonance imaging in detecting T1-T2 head and neck squamous cell carcinoma

The aim of this study was to assess and compare the diagnostic accuracy of fluorodesoxyglucose positron emission/computed tomography (FDG-PET/CT) and magnetic resonance imaging (MRI) to detect T1-T2 head and neck squamous cell carcinoma (HNSCC). Prospective case series. Thirty-five consecutive patie...

Full description

Saved in:
Bibliographic Details
Published in:The Laryngoscope 2018-02, Vol.128 (2), p.378-385
Main Authors: Chaput, Anne, Robin, Philippe, Podeur, Fabien, Ollivier, Morgan, Keromnes, Nathalie, Tissot, Valentin, Nonent, Michel, Salaün, Pierre-Yves, Rousset, Jean, Abgral, Ronan
Format: Article
Language:English
Subjects:
Aged
Bioengineering
Carcinoma, Squamous Cell - diagnostic imaging
Carcinoma, Squamous Cell - pathology
False Negative Reactions
Female
Fluorodeoxyglucose F18
Head and Neck Neoplasms - diagnostic imaging
Head and Neck Neoplasms - pathology
Human health and pathology
Humans
Life Sciences
Magnetic Resonance Imaging - methods
Magnetic Resonance Imaging - statistics & numerical data
Male
Middle Aged
Nuclear medicine
Observer Variation
Positron Emission Tomography Computed Tomography - methods
Positron Emission Tomography Computed Tomography - statistics & numerical data
Predictive Value of Tests
Prospective Studies
Radiopharmaceuticals
Reproducibility of Results
Sensitivity and Specificity
Squamous Cell Carcinoma of Head and Neck
Tumor Burden
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The aim of this study was to assess and compare the diagnostic accuracy of fluorodesoxyglucose positron emission/computed tomography (FDG-PET/CT) and magnetic resonance imaging (MRI) to detect T1-T2 head and neck squamous cell carcinoma (HNSCC). Prospective case series. Thirty-five consecutive patients with histologically proven T1-T2 HNSCC were prospectively included. All patients underwent pretherapeutic FDG-PET/CT and MRI. Two nuclear medicine physicians and 2 radiologists blindly reviewed all FDG-PET/CT and MRI, respectively. A five-point qualitative scale was used to estimate tumor detection ability. Sensitivity of each modality was compared together using a McNemar test. Interobserver variability was assessed by kappa index (κ) of Cohen statistics. Maximal standardized uptake value (SUV ), metabolic tumor volume (MTV) in FDG-PET/CT, and gadolinium enhancement (%GE) in MRI of each tumor were recorded and compared with T stage using a Mann-Whitney test. Tumor-to-normal tissue ratios in FDG-PET/CT and MRI (TNR and TNR ) were calculated and compared together using a Student t test. Among the 35 primary tumors, 29 were detected by FDG-PET/CT and 22 by MRI. MRI detected none of the six lesions incorrectly identified by FDG-PET/CT. FDG-PET/CT correctly identified seven of the 13 MRI false-negative results. Sensitivity of FDG-PET/CT to detect T1-T2 HNSCC was significantly higher than MRI (83% vs. 63%, P = .015). T stage was significantly correlated with MTV (P = .002) unlike with SUV (P = .06) and %GE (P = .70). TNR was significantly higher than TNR (3.5 ± 3.2 vs. 1.2 ± 0.3, P < .0001). Our study showed a higher diagnostic accuracy of FDG-PET/CT than MRI to detect T1-T2 HNSCC with a good interobserver agreement. 4. Laryngoscope, 128:378-385, 2018.
ISSN:0023-852X
1531-4995
DOI:10.1002/lary.26729